Yale Cancer Center Study Shows Checkpoint Inhibitor Prolongs Survival in Patients With Certain Head and Neck Cancers
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).
Smilow Cancer Hospital celebrates 10th anniversary
Smilow Cancer Hospital at Yale New Haven celebrates 10 years since it opened its doors to a new state-of-the-art inpatient and outpatient 500,000-square-foot cancer care facility. Since that day in October 2009, Smilow Cancer Hospital and Yale Cancer Center have risen to the top echelon as one of the nation’s comprehensive cancer research and care facilities, providing advanced care to patients and families and pioneering cancer research.
Yale Scientists Help Immune System Find Hidden Cancer Cells
Cancer cells are masters at avoiding detection, but a new system developed by Yale Cancer Center scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology.
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
At their most basic level, many of the deadliest diseases are caused by nests of misguided proteins. Most medicines work by attaching themselves to these proteins and temporarily shutting them down. In the 1990s, Yale University scientist Craig Crews and a colleague had a radical idea: What if a drug could destroy a bad protein by making it a target of the body’s own molecular trash disposal machines?
Once-Common Hysterectomy Technique Linked to Worse Uterine Cancer Outcomes
Every year, nearly 700,000 American women have surgery to remove their uterus (hysterectomy) or uterine fibroids (myomectomy). A laparoscopic surgical technique once commonly used in these procedures could be worsening the outcomes for women who have undiagnosed uterine cancer at the time of the procedure, Yale Cancer Center scientists report in the Journal of Clinical Oncology.
Yale Cancer Center Researchers Show Adding Radiation After Immunotherapy Improves Survival Time for Patients with Advanced Lung Cancer
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
Yale Cancer Center scientist urges widespread HPV vaccinations
It’s a two-shot vaccination that helps prevent six types of cancer. The vaccine prevents infection by the human papillomavirus, the most common sexually transmitted infection, 95 percent of the time, said Linda Niccolai, a professor of epidemiology at the Yale School of Public Health and an associate of the Yale Cancer Center.